Français Néerlandais Japonais Chinois Allemand Espagnol Portugais

AstraZeneca ramps up investment in Dunkerque

04 Nov 2013 | Investment, Health Nutrition

AstraZeneca will invest €26 million in a new production line for the Symbicourt asthma inhaler at its Dunkerque plant. Existing lines will also be upgraded.

AstraZeneca -  pharmaceutical laboratory - Symbicort - health - Lille Region

            Present in Dunkerque for over 20 years, pharmaceutical giant AstraZeneca has invested some €500 million in its local plant to date—outlays that reflect the facility’s strategic importance as the world’s sole producer of Symbicort inhalers. With demand for the asthma remedy on the rise, the plant needed new capacity. “The aerosol technology we use for this inhaler is fairly unique within our group, and is concentrated at Dunkerque,” says Plant Manager Dominique Bretaudeau.

            The plant, which exports 95% of its total output to the United States, has a long tradition of meeting challenges and adapting to changing patient needs. In addition to special projects, it invests around €2.5 million a year to upgrade and maintain equipment, enhance patient safety and improve packaging.

            AstraZeneca is one of the world’s top pharmaceutical companies and ranks fifth in the field in France. Its medicines cover six main therapeutic areas: cardiovascular & metabolic, infection, gastrointestinal, oncology, neurosciences and respiratory ailments. Sales total around $28 billion, with over $4 million invested in R&D each year.

 

Source: AstraZeneca / Press

Back to news

News

Saica invests €41M in its Aisne site

Saica, the Spanish specialist in recycling paper for corrugated cardboard, is upgrading its Aisne plant in the Hauts-de-France region with the installation of a boiler that meets Rev3 energy transition...

AlkorDraka taken over by a Canadian company

The industrial pride of Picardy, based in the Oise region, and Alkor Medical Tubing have been taken over by Canadian General Tower.

All news